Guides & Research

GLP-1 receptor agonists have revolutionized weight loss treatment. Learn how these medications work, their benefits, and what to expect.

GLP-1 drugs like Ozempic and Wegovy are not safe for everyone. Learn the medical contraindications, black-box warnings, and who should avoid these weight loss injections before talking to your doctor.

Not all GLP-1 drugs cause the same side effects. Compare nausea, vomiting, diarrhea, and serious adverse events across Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda — with actual clinical trial percentages.

Insurance coverage for Wegovy, Zepbound, Ozempic, and other GLP-1 drugs is complex and constantly changing. This 2026 guide explains what Medicare, Medicaid, and commercial insurance cover — and exactly how to fight a prior authorization denial.

Studies show most patients regain significant weight after stopping GLP-1 drugs — often two-thirds of what they lost within one year. Understand the rebound biology, timeline, and evidence-based strategies to minimize weight regain.

If GLP-1 medications aren't accessible — due to cost, shortages, medical contraindications, or insurance — these evidence-based alternatives can still produce meaningful weight loss. We compare every option from FDA-approved drugs to structured lifestyle interventions.

Both Ozempic and Wegovy contain semaglutide, but they're approved for different uses. Understand the key differences in dosing, cost, and insurance coverage.

The GLP-1 landscape is rapidly evolving with exciting new medications in clinical trials. Here is what to expect in the near future.

What does six months on semaglutide actually look like? We break down the clinical trial data, real-world averages, and the variables that separate top responders from modest ones.

Nausea is the most common reason people quit tirzepatide early. Here's the mechanism behind it, a week-by-week timeline, and a tiered management approach that lets most patients push through.

BMI thresholds, qualifying comorbidities, insurance requirements, and the nuanced clinical picture of GLP-1 eligibility — everything you need to prepare for the conversation with your doctor.

Both drugs contain semaglutide. Both are made by Novo Nordisk. Yet Wegovy and Ozempic have different FDA indications, dosing ceilings, insurance pathways, and clinical profiles. Here's the complete breakdown.

On Mounjaro, eating less doesn't automatically mean eating smarter. This full 7-day, protein-first meal plan is designed specifically for the reduced appetite, GI sensitivities, and muscle-preservation demands of tirzepatide therapy.

Constipation is more common and more persistent than nausea on semaglutide — and it's rarely discussed. Here's the mechanism, the clinical evidence, and a practical daily protocol for managing it.

There is no official GLP-1 diet. But the specific physiology of these medications — slowed gastric emptying, suppressed appetite, protein imperatives — demands a food approach tailored to the drug. Here is that guide.

Sulfur burps on Mounjaro or Zepbound have identifiable causes and manageable solutions. Here's what actually produces them and what works to reduce them.

Without insurance, semaglutide can cost over $1,300 per month. But most patients paying out-of-pocket pay far less — once they know all the options. Here's the complete 2026 cost landscape.

This class of medications is among the most rigorously studied in cardiology. The overall cardiovascular picture is positive — but there are real signals worth understanding, and important gaps in the long-term data.

PCOS affects 1 in 10 women and makes weight loss exceptionally difficult. Here's what the research says about semaglutide for PCOS patients.

Rybelsus is the only oral GLP-1 on the market. How does it compare to injectable options like Ozempic and Wegovy on efficacy, side effects, and cost?

Starting semaglutide can be anxiety-inducing. Here's exactly what to expect during your first week — day by day — so you know what's normal.

The SURMOUNT and STEP trials provide the clearest comparison yet. Here's what 72 weeks of data actually shows about these two leading medications.

Exercise on GLP-1 medications requires a different approach. Here's a safe, progressive plan designed specifically for patients on these drugs.

Zepbound availability has improved but finding it can still be challenging. Here's how to find clinics, navigate insurance, and access tirzepatide.

Nighttime acid reflux is an underreported side effect of semaglutide. Here's why it happens and evidence-based strategies to prevent it.

When your appetite is suppressed, protein shakes are often the easiest way to hit your daily protein target. Here are recipes designed for GLP-1 users.

Liraglutide was the first GLP-1 for weight loss. With newer options available, does it still make sense? Here's an honest assessment.

Fatigue on Trulicity is more common than clinical trial numbers suggest. Here's why it happens and what actually helps.

The definitive comparison of every FDA-approved GLP-1 medication: weight loss data, dosing, cost, side effects, insurance, and how to choose the right one for your clinical situation.

Compounded semaglutide costs a fraction of branded Wegovy — but comes with real safety, regulatory, and quality considerations that every patient should understand before using it.

The worst of the GLP-1 shortage era (2022–2024) is over — but availability is still uneven across drugs, doses, and pharmacies. Here's the current status and what to do if your medication is hard to find.

GLP-1 medications interact with several drug classes — from insulin and oral diabetes medications to blood thinners and oral contraceptives. This medically reviewed guide covers every clinically significant interaction you need to discuss with your prescriber.

GLP-1 medications are contraindicated in pregnancy — but the timing of stopping, the risk of accidental exposure, and what happens after delivery are nuanced. This guide covers what every woman of childbearing age on GLP-1 therapy needs to know.

Most GLP-1 side effect research covers 68–72 weeks. What happens to your thyroid, kidneys, heart, muscle, and bones over years of treatment? This is everything the long-term data actually shows.

"Ozempic face" — the gaunt, hollow appearance some patients develop from rapid weight loss — is real. So is the loss of lean muscle. Here's the science behind both, and the evidence-based strategies that actually minimize them.

GLP-1 receptors exist throughout the brain and body — in addiction circuits, dopamine pathways, inflammatory systems, and possibly amyloid plaques. This is the research frontier: what early trials and real-world observations reveal about GLP-1 uses beyond weight loss.